Resources
83 Results (showing 1 - 10)
Results sorted by posted date (newest first)
Results sorted by posted date (newest first)
Posted 5/17/2024
The Alcohol-Related Disease Impact (ARDI) is an online application from the Centers for Disease Control and Prevention (CDC) that provides national and state estimates of alcohol-related health impacts, including deaths and years of potential life lost (YPLL).
Posted 4/12/2024
This peer reviewed journal article OUD treatment and pregnancy outcomes among pregnant patients receiving OUD care through a telehealth addiction treatment program in the US. The patients identified in the study received buprenorphine or buprenorphine and naloxone treatment.
Posted 3/29/2024
The Centers for Disease Control and Prevention (CDC) has naloxone trainings and fact sheets available for clinicians. The trainings and fact sheets can help clinicians raise awareness about the benefits of naloxone by talking with patients and their family, friends, and caregivers.
Posted 3/10/2024 (updated 3/28/2024)
The Substance Abuse and Mental Health Services Administration's (SAMHSA) updated Overdose Prevention and Response Toolkit provides guidance to a wide range of individuals on preventing and responding to an overdose. It emphasizes harm reduction and access to treatment as essential aspects of overdose prevention.
Posted 2/2/2024 (updated 3/28/2024)
The U.S. Department of Health and Human Services' Office of Minority Health provided a brief in November 2023 assessing whether and how rates of substance use and substance use disorder (SUD) among adults (ages 18 and older) differ by race and ethnicity.
Posted 1/19/2024 (updated 3/28/2024)
The FDA announced that the manufacturer of NARCAN 4 mg Nasal Spray products, Emergent BioSolutions, has extended the shelf-life of their product from 3 years to 4 years. This new extension of shelf-life was requested by the FDA to help prevent overdoses and reduce overdose-related deaths.
Posted 12/1/2023 (updated 3/28/2024)
The Substance Abuse and Mental Health Services Administration (SAMHSA) released results of the 2022 National Survey on Drug Use and Health (NSDUH). The NSDUH provides information on substance use and mental health rates in the United States with data on the self-reported use of tobacco, alcohol, and illicit drugs; substance use disorders; mental health conditions; and suicidal thoughts and behaviors. SAMSHA also released a high-level brief of the report with infographics.
Posted 10/23/2023 (updated 3/27/2024)
Posted 7/31/2023 (updated 3/26/2024)
At the end of July 2023, the U.S. Food and Drug Administration approved a second over-the-counter naloxone nasal spray product, RiVive. The agency who received the approval to manufacture the product, Harm Reduction Therapeutics, does not yet have a timeline of availability and decision on pricing.
RSV 2023 Session: Quick Response Teams: Preventing Deaths While Sharing the Hope of Recovery (Day 1)
Posted 7/26/2023 (updated 3/28/2024)
The presentation discussed the development and changes in the utilization of a Quick Response Team in an Ohio rural community.